Table 2 Risk management performance and postdisclosure diagnoses among eligible participants without prior genetic diagnosis.

From: Clinical outcomes of a genomic screening program for actionable genetic conditions

 

FH (n = 93)

HBOC (n = 163)

Lynch (n = 49)

All (n = 305)

Risk management eligiblea

93/93 (100%)

114/163 (69.9%)

48/49 (98.0%)

255/305 (83.6%)

Risk management predisclosureb

69/93 (74.2%)

43/114 (37.7%)

11/48 (22.9%)

123/255 (48.2%)

Risk management postdisclosurec

78/93 (83.9%)

82/114 (71.9%)

19/48 (39.5%)

179/255 (70.2%)

New diagnosis postdisclosured

26/93 (28.0%)

10/163 (6.1%)

5/49 (10.2%)

41/305 (13.4%)

  1. FH familial hypercholesterolemia, HBOC hereditary breast and ovarian cancer syndrome.
  2. aEligible by age, sex, and prior treatment to have risk management per published guidelines during postdisclosure analysis period.
  3. bHad at least one risk management procedure within recommended time period prior to genetic results disclosure.
  4. cHad at least one risk management procedure during postdisclosure follow-up period.
  5. dDiagnosis of relevant disease or clinical finding during postdisclosure follow-up period.
Back to article page